Sign in
Enrolling by invitationPhase 4

Comparison of the Effect of Gonadotropin and Clomiphene Citrate Treatment on Sperm Parameters and the Outcome of Assisted Reproductive Procedures in Subfertile Men Based on the APHRODITE Groups

Key facts

Who runs it
Szeged University
Where
Hungary1 site in 1 countryChoose a country to see its sites
Trial code
Status
Enrolling by invitation
Phase
Phase 4
People taking part
500 people, planned
Started
1 Sept 2024
Expected to end
1 Dec 2026
Type of study
Interventional, 5 groups
Treatments tested
  • recFSH
  • HCG injection
  • Clomiphene Citrate 50 mg
Record updated
16 April 2026

Who can take part

Age
18 years and older
Sex
Men only
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 5 criteriaShow less

Who can take part

  • abnormal sperm analysis result, APHRODITE 2,3,4 categories

Who cannot take part

  • non-obstructive azoospermia due to genetical defects (Klinefelter-syndrome, AZFa, AZFb microdeletion syndrome etc)
  • obstructive azoospermia
  • problems with the administration of subcutaneous injections
  • disagreement

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

Men enrolled in the study are assigned to each APHRODITE group. Group 2,3,4 are treated with either gonadotropin preparations or clompihene-citrate (except group 4). The type of the treatment (gonadotropin vs clomiphene) is randomized. After treatment, hormonal measurements, spermiogram and DNA fragmentation tests are repeated, allowing for analysis of the outcome.

The 5 groups in the trial

  • APHRODITE category 2 treated with gonadotropinTreatment being tested

    subcutaneous recFSH 3x150NE weekly for 12 weeks

    Treatment: recFSH

  • APHRODITE category 2 treated with clomiphene-citrateTreatment being tested

    per os 50mg clomiphene-citrate daily for 12 weeks

    Treatment: Clomiphene Citrate 50 mg

  • APHRODITE category 3 treated with gonadotropinTreatment being tested

    subcutaneous recFSH 3x150NE weekly and subcutaneous hCG 2x5000NE weekly for 12 weeks

    Treatment: recFSH and HCG injection

  • APHRODITE category 3 treated with clomiphene-citrateTreatment being tested

    per os 50mg clomiphene-citrate daily for 12 weeks

    Treatment: Clomiphene Citrate 50 mg

  • APHRODITE category 4 treated with gonadotropinTreatment being tested

    subcutaneous hCG 2x5000NE weekly for 12 weeks, if FSH level drops below 1.5 IU/l, subcutaneous recFSH 3x150NE weekly added

    Treatment: recFSH and HCG injection

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Record updated
16 April 2026